Trial · NCT00490100
Treatment for Growth Failure in Patients With X-Linked Severe Combined Immunodeficiency: Phase 2 Study of Insulin-Like Growth Factor-1
NCT00490100, Phase 1, Phase 2, Terminated, National Institute of Allergy and Infectious Diseases (NIAID); results first posted 2015-07-03
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Treatment for Growth Failure in Patients With X-Linked Severe Combined Immunodeficiency: Phase 2 Study of Insulin-Like Growth Factor-1. Trials, record NCT00490100. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00490100
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Treatment for Growth Failure in Patients With X-Linked Severe Combined Immunodeficiency: Phase 2 Study of Insulin-Like Growth Factor-1
- NCT number
- NCT00490100
- Status
- Terminated
- Phases
- Phase 1, Phase 2
- Enrollment
- 6 participants, actual
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- Conditions
- Growth Failure, X-linked Severe Combined Immunodeficiency (XSCID), Growth Hormone Resistence
- Interventions
- Increlex
- First posted
- 2007-06-22
- Last updated
- 2015-07-03
- Results first posted
- 2015-07-03
- Limitations and caveats
- Due to limited subject participation, there is insufficient complete data to generate meaningful statistics for the outcome measures. Instead, this data will be reported as a case series.
Source ClinicalTrials.gov
Registered outcomes2
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Safety of Study Drug | 1 year | Rates of adverse events related to study drug |
| Primary | Change in Growth Rate on Study Drug | During intervention, up to 2 years | Growth rate on intervention is compared with growth rate before intervention for each participant. |
Source ClinicalTrials.gov
Outcomes2
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Safety of Study Drug | 1 year | participants | NUMBER | |
| PRIMARY | Change in Growth Rate on Study Drug | During intervention, up to 2 years | Only participants who completed study | cm/year | MEDIAN |
Source ClinicalTrials.gov
Results by group2
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Safety of Study Drug | Treatment | 0 | participants | ||
| Change in Growth Rate on Study Drug | Treatment | 5.2 | Full Range 1.2 to 8.6 | cm/year |
Source ClinicalTrials.gov
Participant flow3
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Treatment | 6 | |
| Overall Study | COMPLETED | Treatment | 3 | |
| Overall Study | NOT COMPLETED | Treatment | 3 |
Source ClinicalTrials.gov
Adverse events4
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Diarrhea (clostridium diff) | Gastrointestinal disorders | Treatment | 1 | 6 | |
| other | Lower gastrointestinal hemorrhage | Gastrointestinal disorders | Treatment | 1 | 6 | |
| other | Lung infection | Infections and infestations | Treatment | 2 | 6 | |
| other | Myalgia | Musculoskeletal and connective tissue disorders | Treatment | 1 | 6 |
Source ClinicalTrials.gov
Adverse event totals3
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Treatment | ||
| Total, other adverse events | Treatment | 4 | 6 |
| Total, serious adverse events | Treatment | 0 | 6 |
Source ClinicalTrials.gov
Papers3
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT00490100
GET https://conductscience.org/api/trials/v1/NCT00490100/registered